The Tube Versus Trabeculectomy (TVT) Study is a multicenter randomized clinical trial comparing the safety and efficacy of tube-shunt surgery to trabeculectomy with mitomycin (MMC) in eyes with previous cataract and/or unsuccessful glaucoma surgery. This article reviews published results from the TVT Study.
Introduction
Despite the introduction of several new incisional-glaucoma procedures in recent years, trabeculectomy and tube-shunt surgery remain the most frequently performed glaucoma operations in the USA. Medicare data show a steady reduction in the number of trabeculectomies performed between 1995 and 2004, and a concurrent rise in tube-shunt surgery has occurred [1] . Surveys of the American Glaucoma Society membership also demonstrate a growing preference for tube shunts and a decline in the popularity of trabeculectomy in various clinical settings [2, 3] . Concern about bleb-related complications, such as bleb leaks and bleb infections, have likely contributed to the expanded use of tubeshunt surgery as an alternative to trabeculectomy. When tube shunts were introduced, they were generally reserved for refractory glaucomas at high risk for failure with filtering surgery. However, an increasingly positive experience with these devices has prompted their implantation in glaucomas with better surgical prognoses. No clear consensus exists among glaucoma surgeons regarding the preferred surgical approach for managing glaucoma in eyes with previous-ocular surgery [2, 3] . In particular, some surgeons favor an antifibrotic-augmented trabeculectomy, whereas others prefer placement of a tube-shunt in eyes with prior cataract or failed filtering surgery.
The Tube Versus Trabeculectomy (TVT) Study is a multicenter randomized clinical trial comparing the safety and efficacy of tube-shunt surgery to trabeculectomy with mitomycin C (MMC) in eyes with prior-ocular surgery. Patients with uncontrolled glaucoma who had previously undergone cataract extraction with intraocular-lens implantation and/or unsuccessful trabeculectomy were randomized to receive a 350 mm 2 Baerveldt-glaucoma implant or trabeculectomy with MMC. The goal of this investigator-initiated study is to provide valid evidencebased information that will assist surgical-decision making in these patient groups.
Study design
The design and methods of the TVT Study were previously described in detail [4] . The study is registered with http://www.clinicaltrials.gov (NCT00306852). The inclusion and exclusion criteria for the study are listed in Table 1 . Enrolled patients were randomly assigned to treatment with a tube-shunt or trabeculectomy with MMC. Patients in the tube group underwent placement of a 350 mm 2 Baerveldt-glaucoma implant in the superotemporal quadrant with a complete restriction of flow at the time of implantation. Patients in the trabeculectomy group had a trabeculectomy superiorly with a standard dosage of MMC of 0.4 mg/ml for 4 min. All of the investigators were glaucoma surgeons who were experienced in performing both of the surgical procedures under study. Follow-up visits were scheduled 1 day, 1 week, 1 month, 3 months, 6 months, 1 year, 18 months, 2 years, 3 years, 4 years, and 5 years postoperatively. Each examination included measurement of Snellen-visual acuity, intraocular pressure (IOP), slit-lamp biomicroscopy, Seidel testing, and ophthalmoscopy. Standard automated perimetry, best-corrected visual acuity on Early Treatment Diabetic Retinopathy Study (ETDRS) charts, and quality of life assessment with the National Eye Institute Questionnaire (NEI VFQ-25) were performed at baseline and at the annual follow-up visits. A formal motility evaluation was performed in all patients at baseline and at the 1-year and 5-year follow-up visits, and at any other visits after 3 months if the patient reported diplopia. The examining clinician provided a reason for loss of two or more lines of Snellen visual acuity at followup visits after 3 months.
Failure was prospectively defined as IOP more than 21 mmHg or not reduced by 20% below baseline on two consecutive follow-up visits after 3 months, IOP 5 mmHg or less on two consecutive follow-up visits after 3 months, reoperation for glaucoma, or loss of lightperception vision. Reoperation for glaucoma or a complication was defined as additional intervention that required a return to the operating room. Cyclodestruction was also counted as a reoperation for glaucoma, and a vitreous biopsy with injection of intravitreal antibiotics was a reoperation for a complication. Serious complications were defined as surgical complications that were associated with loss of two or more lines of Snellen visual acuity and/or reoperation to manage the complication.
Baseline characteristics
A total of 212 eyes of 212 patients were enrolled at 17 Clinical Centers, including 107 in the tube group and 105 in the trabeculectomy group [4] . The mean age of the study population was 71.0 years, and 53% were women. The baseline IOP was 25.3 AE 5.3 mmHg (mean AE SD) on 3.1 AE 1.2 glaucoma medications (mean AE SD), and 81% of patients had primary openangle glaucoma. Among enrolled patients, 44% had undergone cataract surgery, 35% trabeculectomy, and 20% combined cataract and glaucoma surgery as the qualifying previous ocular surgery for the study. The demographic and ocular characteristics were not significantly different between the tube group and the trabeculectomy group, suggesting that randomization was very effective in generating two balanced treatment groups. 
Operative data and postoperative interventions
All enrolled patients received the assigned surgical treatment. A majority of patients had a fornix-based conjunctival flap in the tube group (77%) and a limbus-based conjunctival flap in the trabeculectomy group (74%) [5] . An external polyglactin ligature was the most common method of tube occlusion (75%), and tube fenestration was frequently performed (77%) for IOP reduction in the early postoperative period.
The most commonly performed postoperative intervention was laser suture lysis (49%) in the trabeculectomy group and rip-cord removal (18%) in the tube group [5] . Needling procedures were infrequently performed in the trabeculectomy group (8%) and the tube group (2%) during the first year of follow-up, and were not considered glaucoma reoperations. Several patients in the trabeculectomy group (22%) received adjunctive subconjunctival injections of 5-fluorouracil.
Intraocular pressure and medical therapy
Data on IOP and glaucoma-medical therapy at baseline and at the annual follow-up visits are presented in Table 2 . Patients who underwent additional glaucoma surgery were censored from analysis after reoperation. The trabeculectomy group had significantly lower mean IOPs than the tube group at all follow-up visits during the first 3 months, but no significant difference in the degree of IOP reduction persisted between treatment groups after 3 months [6, 7 ] . Adjunctive-medical therapy use was significantly greater in the tube group compared with the trabeculectomy group at all followup visits during the first 2 postoperative years. However, no significant difference in the mean number of medications was present between treatment groups at 3 years [7 ] .
Surgical success
The cumulative probability of failure was 15.1% in the tube group and 30.7% in the trabeculectomy group at 3 years, a difference that was statistically significant (P ¼ 0.010, log rank test adjusted for stratum) [7 ] . Kaplan-Meier plots of the probability of failure are shown in Fig. 1 Adapted from [7 ] .
but this difference did not quite reach the level of statistical significance (P ¼ 0.091, log rank test adjusted for stratum).
Visual acuity
Reduction in visual acuity occurred in both the tube group and the trabeculectomy group during the first 3 years of follow-up, but Snellen and ETDRS visual acuity were similar between treatment groups at 3 years [7 ] . The rate of loss of two or more lines of Snellen visual acuity was not significantly different between the tube group (31%) and the trabeculectomy group (34%) after 3 years (P ¼ 0.65, log rank test). Many of the causes of vision loss were not directly attributable to the surgical procedures under study, such as macular degeneration and diabetic retinopathy. However, the proportion of patients who lost two or more Snellen lines was significantly higher for patients who developed postoperative complications (45%) than patients without complications (20%) after 1 year of follow-up (P < 0.001, chisquare test) [5] .
Surgical complications
Although a substantial number of surgical complications developed in the TVT Study, most were transient and self-limited. A similar rate of intraoperative complications was observed in the tube group (7%) and trabeculectomy (10%) (P ¼ 0.59, chi-square test) [5] . Significantly more patients in the trabeculectomy group (60%) experienced postoperative complications compared with the tube group (39%) during the first 3 years of follow-up (P ¼ 0.004, chi-squared test) [7 ] . However, all complications are not equal in severity, and serious complications associated with reoperation to manage the complication and/or loss of two Snellen lines of vision occurred with similar frequency in the trabeculectomy group (27%) and tube group (22%) at 3 years (P ¼ 0.58, chi-square test). Wound leaks (P ¼ 0.004, chi-squared test), dysesthesia (P ¼ 0.018, Fischer's exact test), and bleb leaks (P ¼ 0.028, Fisher's exact test) were significantly more common in the trabeculectomy group compared with the tube group. New-postoperative motility disturbances developed more frequently in the tube group (9.9%) than the trabeculectomy group (0%) during the first year of follow-up (P ¼ 0.005, Fisher's exact test) [8 ] , and there was a tendency for diplopia to occur more commonly in the tube group (5%) compared with the trabeculectomy group (0%) (P ¼ 0.06, Fisher's exact test) [5,7 ,8 ] .
In multivariate risk factor analyses after 1 year of followup, persistent-corneal edema (P < 0.001, exact permutation logistic regression) and choroidal effusion (P ¼ 0.001, exact permutation logistic regression) were significant independent predictors of vision loss [5] . Wound leaks (P ¼ 0.026, exact permutation logistic regression) and hypotony maculopathy (P ¼ 0.049, exact permutation logistic regression) were significantly associated with treatment failure. Shallowing of the anterior chamber significantly increased the risk of cataract progression (P ¼ 0.008, exact permutation logistic regression).
Cataract progression
Cataract progression was common in the TVT Study, but occurred with similar frequency in the tube group (58%) and the trabeculectomy group (57%) during the first 3 years of follow-up (P ¼ 1.00, chi-squared test) [7 ] . The rate of cataract surgery was not significantly different between the tube group (46%) and the trabeculectomy group (29%) after 3 years (P ¼ 0.38, chi-squared test).
Conclusion
The TVT Study enrolled patients with medically uncontrolled glaucoma who had previous cataract extraction with intraocular-lens implantation and/or failed-filtering surgery and randomly assigned treatment to trabeculectomy with MMC or tube-shunt placement.
Patients who were treated with tube-shunt surgery were more likely to maintain IOP control and avoid persistent hypotony, loss of light-perception vision, or reoperation for glaucoma than trabeculectomy with MMC during the first 3 years of follow-up [7 ] . Both surgical procedures were associated with similar IOP reduction and use of supplemental medical therapy at 3 years. The incidence of postoperative complications was higher after trabeculectomy with MMC compared with tubeshunt surgery, but serious complications associated with reoperation and/or vision loss occurred with similar frequency with both surgical procedures. The rate of vision loss after trabeculectomy with MMC and tubeshunt surgery was not significantly different after 3 years of follow-up. Cataract progression was common, but occurred with similar frequency with both surgical procedures.
The TVT Study challenges several current concepts and recent publications about the safety and efficacy of incisional-glaucoma surgery. Based upon a systematic review of the medical literature on tube shunts, a panel of glaucoma specialists concluded that low-IOP levels usually cannot be attained with these devices and the IOP typically settles in the high teens, postoperatively [9 ] . The TVT Study contradicts these opinions, as evidenced by a mean IOP of 13.0 mmHg and IOP of 14 mmHg or less in 62% of patient in the tube group at 3 years [7 ] . Wilson et al. [10] conducted a randomized clinical trial in Sri Lanka comparing the Ahmed glaucoma-valve implant (New World Medical, Inc., Rancho Cucamonga, California, USA) to trabeculectomy with or without an adjunctive antifibrotic agent in patients with primary open angle glaucoma or angle-closure glaucoma and no previous ocular surgery. With an average follow-up of 31 months, success rates were comparable between the trabeculectomy group and the Ahmed group. In contrast, the TVT Study found that tube-shunt surgery had a higher success rate compared with trabeculectomy with MMC after 3 years of follow-up [7 ] . In a retrospective review of data derived from Medicare claims, Stein et al. [11 ] found higher rates of adverse outcomes after tube-shunt surgery than primary trabeculectomy or trabeculectomy with scarring. The opposite observation was made in the TVT Study, with a higher rate of postoperative complications after trabeculectomy with MMC relative to tube-shunt surgery [5, 7 ] . The differences in results between the TVT Study and other studies likely relates to differences in study populations, implant types, surgical techniques, outcome measures, and study designs. Importantly, the TVT Study excluded several types of refractory glaucomas that have historically undergone tube-shunt surgery (e.g., neovascular glaucoma) and included patients at lower risk for failure after trabeculectomy than have traditionally had placement of a tube shunt (e.g., only prior clear corneacataract extraction).
There are several limitations to the TVT Study. The study enrolled patients who met specific inclusion and exclusion criteria, and the results should not be generalized to different patient groups. An attempt was made to standardize the two glaucoma procedures under investigation, but variations in surgical technique are expected with different surgeons. The low incidence of certain complications and the small size of many patient subgroups limit the power of the study to detect significant differences. There were no standardized definitions or quantification of surgical complications. A limbus-based conjunctival flap was used in most patients randomized to the trabeculectomy group, and MMC (0.4 mg/ml) was applied intraoperatively for 4 min. A trend toward use of fornix-based conjunctival flaps with a more diffuse application of MMC at a lower dosage has developed since the TVT Study was initiated [12] . This modification in surgical technique may result in lower rates of hypotony and bleb-related complications after trabeculectomy [13] . A subgroup of patients enrolled in the TVT Study (i.e., those with a history of prior trabeculectomy with MMC) had already failed one treatment arm of the study, and potentially could have introduced bias in favor of the tube group. We felt that the study question of whether one surgical procedure was superior to the other was clinically relevant in eyes that had failed a MMC trabeculectomy, and a separate stratum (stratum 4) was created for these eyes to facilitate data analysis and address con-cerns about possible bias. No significant differences in treatment efficacy were observed between strata.
The results of the TVT Study provide further support for the expanded use of tube shunts beyond refractory glaucomas. Although these devices have historically been reserved for surgically managing glaucomas at high risk of trabeculectomy failure, this study enrolled eyes at lower risk for failure. The TVT Study does not demonstrate clear superiority of one glaucoma operation over the other. Other factors that must be considered when selecting a surgical procedure include the surgeon's skill and experience with both operations, the patient's willingness to undergo repeat glaucoma surgery, and the planned surgical approach should failure occur. Additional follow-up data will be forthcoming, and is needed to fully assess the risks and benefits of tube-shunt surgery and trabeculectomy with MMC in managing medically uncontrolled glaucoma in similar patient groups.
